Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Jian-An Huang et al.|Unknown|2011Cited by 5